---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-139364"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:20:37.337318+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics Q1 net loss $12.7M; SPR720 Phase 2a data expected 2H 2024

## Summary
- Net loss $12.7M ($0.24/share) vs $13.3M ($0.25/share) in Q1 2023; revenue $9.3M up from $2.1M.
- Cash $82.3M at March 31, 2024, increased from $76.3M after receiving $23.8M milestone from GSK for tebipenem HBr.
- SPR720 Phase 2a top-line data for NTM-PD expected 2H 2024; tebipenem HBr Phase 3 PIVOT-PO enrollment ongoing, completion 2H 2025.
- SPR206 received FDA Fast Track designation for HABP/VABP due to CRABc and CRPA; Phase 2 contingent on non-dilutive funding.
- Reaffirmed cash runway into late 2025 based on current operating plans.

## SEC filing metadata
- accession: 0001193125-24-139364
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312524139364/0001193125-24-139364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312524139364/d756109d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-139364
- JSON: https://secwatch.observer/filing/0001193125-24-139364.json
- Plain text: https://secwatch.observer/filing/0001193125-24-139364.txt

## Key facts
- Earnings Releases
  Spero Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $9.3 million, net income net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted, EPS ($0.24) per share.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $9.3 million
  - Net income: net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted
  - EPS: ($0.24) per share
  - Result: reported results
  source text: net loss of $13.3 million, or ($0.25) per share of common stock, basic and diluted, for the first quarter ended March 31, 2023. • Total revenue for the first quarter of 2024 was $9.3 million, compared with total revenue of $2.1 million for the first quarter of 2023. The revenue increase for the first quarter of 2024 was primarily due to an increase in collaboration
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312524139364/0001193125-24-139364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.